-
A Breakthrough in Diabetes Care: SAB-142 Receives FDA Fast Track Designation
NASDAQ: $SABS New Hope for Type 1 Diabetes Treatment The landscape of diabetes management is shifting as SAB Biotherapeutics recently announced a significant milestone for their investigative therapy, SAB-142. The FDA has officially granted Fast Track designation to this novel treatment, aimed at patients currently in Stage 3 Type 1 diabetes. What is SAB-142? SAB-142…
-
Advancing Type 1 Diabetes Care: Mozart Therapeutics Shares New Data on MTX-101
A New Frontier in Autoimmune Research At the 62nd EASD Annual Meeting, Mozart Therapeutics took center stage to share critical updates regarding their lead therapeutic candidate, MTX-101. This presentation marks an important milestone for the company as they continue to investigate novel ways to treat autoimmune diseases, specifically focusing on Type 1 Diabetes (T1D). Understanding…
-
Bayer’s Kerendia (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026 — Bayer today announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated… Source: Read More
-
A Breakthrough in Diabetes Care: Tzield Approved as First Disease-Modifying Therapy for Type 1 Diabetes
NASDAQ: $SNY A New Era for Type 1 Diabetes Treatment In a significant milestone for medical science, the FDA has officially approved Tzield (teplizumab-mzwv). This approval marks the introduction of the first-ever disease-modifying therapy for individuals at risk of developing clinical stage 3 Type 1 diabetes. Understanding the Breakthrough For decades, treatment for Type 1…